ISSN 1662-4009 (online)

ey0019.12-1 | New data on the epidemiology of T2DM in children | ESPEYB19

12.1. Worldwide estimates of incidence of type 2 diabetes in children and adolescents in 2021

AOY Wu H, Patterson CC, Zhang X, Ghani RBA, Magliano DJ, Boyko EJ, Ogle GD, Luk

Diabetes research and clinical practice 2022;185:109785. doi: 10.1016/j.diabres.2022.109785Brief Summary: This systematic review estimated 41 600 new incident cases of T2DM in children under age 20 years globally in 2021.Comment: Worldwide estimates of T2DM incidence in children and adolescents under 20 years, both at regional and national levels, were reached by ...

ey0019.13-9 | Diabetes | ESPEYB19

13.9. Global estimates of incidence of type 1 diabetes in children and adolescents: results from the International Diabetes Federation atlas, 10th edition

GD Ogle , S James , D Dabelea , C Pihoker , J Svennson , J Maniam , EL Klatman , CC Patterson

grahamo@diabetesnsw.com.au Diabetes Res Clin Pract 2022, 183:109083. doi: 10.1016/j.diabres.2021.109083Brief Summary: The incidence of Type 1 diabetes (T1D) in children and adolescents is increasing in many nations. The 10th edition of the International Diabetes Federation Atlas reports that an estimated 108,300 youth aged < 15 years a...

ey0017.9-6 | Fertility-Related Issues | ESPEYB17

9.6. Assessment of ovarian function in adolescents and young adults after childhood cancer treatment-How accurate are young adult/parent proxy-reported outcomes?

SA George , R Williamson Lewis , L McKenzie , B Cherven , BC Patterson , KE Effinger , AC Mertens , LR Meacham

To read the full abstract: Pediatr Blood Cancer. 2019;66(12):e27981. sgeorg4@emory.eduThis cross-sectional study tested the concordance between young adult (or parent proxy)-reported premature ovarian insufficiency (POI) and biochemical evidence of POI, defined as FSH ≥40 mIU/ml, in 182 childhood cancer survivors (CCS) who had received gonadotoxic therapy. Reported POI was defined as the survivor taki...

ey0017.14-8 | (1) | ESPEYB17

14.8. Patient-customized oligonucleotide therapy for a rare genetic disease

J Kim , C Hu , C Moufawad El Achkar , LE Black , J Douville , A Larson , MK Pendergast , SF Goldkind , EA Lee , A Kuniholm , A Soucy , J Vaze , NR Belur , K Fredriksen , I Stojkovska , A Tsytsykova , M Armant , RL DiDonato , J Choi , L Cornelissen , LM Pereira , EF Augustine , CA Genetti , K Dies , B Barton , L Williams , BD Goodlett , BL Riley , A Pasternak , ER Berry , KA Pflock , S Chu , C Reed , K Tyndall , PB Agrawal , AH Beggs , PE Grant , DK Urion , RO Snyder , SE Waisbren , A Poduri , PJ Park , A Patterson , A Biffi , JR Mazzulli , O Bodamer , CB Berde , TW. Yu

To read the full abstract: N Engl J Med. 2019 Oct 24;381(17):1644-1652. doi: 10.1056/NEJMoa1813279.This remarkable case report - by authors from Boston Children’s Hospital and funded by Mila’s Miracle Foundation - describes the development and use of a patient-customised antisense oligonucleotide drug that was tailored specifically against the unique DNA sequence mutation in a 6-ye...

ey0020.7-14 | Long-Term Surveillance for Endocrine Complications in Childhood Cancer Survivors | ESPEYB20

7.14. Hypothalamic-pituitary and other endocrine surveillance among childhood cancer survivors

L van Iersel , RL Mulder , C Denzer , LE Cohen , HA Spoudeas , LR Meacham , E Sugden , AYN Schouten-van Meeteren , EW Hoving , RJ Packer , GT Armstrong , S Mostoufi-Moab , AM Stades , D van Vuurden , GO Janssens , C Thomas-Teinturier , RD Murray , N Di Iorgi , SJCMM Neggers , J Thompson , AA Toogood , H Gleeson , C Follin , E Bardi , L Torno , B Patterson , V Morsellino , G Sommer , SC Clement , D Srivastava , CE Kiserud , A Fernandez , K Scheinemann , S Raman , KCJ Yuen , WH Wallace , LS Constine , R Skinner , MM Hudson , LCM Kremer , W Chemaitilly , HM van Santen

Brief summary: In this extensive and updated review, the International Late Effects of Childhood Cancer Guideline Harmonization Group (IGHG) report expert consensus-based guidelines that harmonize recommendations for surveillance of endocrine disorders in childhood cancer survivors.This interdisciplinary panel of 42 international experts formulated new surveillance recommendations for hypothalamic–pituitary (HP) dysfunction. Existing IGHG surveillan...